Related Experiment Videos
Selegiline for Alzheimer's disease
1Department of Geratology, University of Oxford, Oxford, UK, OX2 6HE. jacqueline.birks@geratology.ox.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Selegiline shows promising benefits for Alzheimer's disease patients' memory, mood, and behavior, but more research is needed for routine clinical recommendation.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, affecting approximately 60% of older adults.
- Neurotransmitter dysfunctions are implicated early in AD pathogenesis, influencing cognitive decline.
- Selegiline's efficacy in AD remains controversial due to mixed trial results and regulatory concerns.
Purpose of the Study:
- To systematically review and assess the effectiveness of selegiline in improving the well-being of patients diagnosed with Alzheimer's disease.
Main Methods:
- Conducted a comprehensive search of clinical trials using terms like 'selegiline' and 'l-deprenyl'.
- Included unconfounded, double-blind, randomized controlled trials comparing selegiline to placebo in dementia patients for over one day.
- Extracted and pooled data, primarily using completers' data for meta-analyses, estimating weighted or standardized mean differences.
Main Results:
- Fifteen trials were included, examining cognitive, behavioral, and mood effects.
- Meta-analysis indicated significant benefits of selegiline on memory function and improvements in mood and behavior.
- Global rating scales showed no effect, and evidence on standardized cognitive scales was limited; adverse effects were recorded but rarely led to trial withdrawal.
Conclusions:
- While selegiline shows promising effects for Alzheimer's disease patients, current evidence is insufficient for routine clinical recommendation.
- Further research, including individual patient data reviews and studies on standardized cognitive scales, is necessary to clarify selegiline's role.